Astrazeneca Pharmaceuticals

China, AstraZeneca

AstraZeneca overhauls management of its China division, FT reports

AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general manager, the Financial Times reported on Friday, citing two people with direct knowledge of the matter.

Seeking Alpha on MSN · 1d

AstraZeneca said to have changed management of its China unit

AstraZeneca (AZN) changes key management roles in China as the company emerges from several scandals involving its executives there. Read more here.

The Financial Times · 1d

AstraZeneca overhauls management of its scandal-hit China division

The scandal ensnared the China president Leon Wang, who the company announced in November had been detained, along with several other employees. AstraZeneca shed more than £15bn off its market capitalisation after reports about an investigation by local authorities.

US FDA approves AstraZeneca's drug for breast cancer

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

1don MSN

FDA approves new MCL treatment by AstraZeneca

WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® ...

AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline

AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...

AstraZeneca Pharma share price rises 3% on CDSCO nod for Eculizumab

AstraZeneca share rose after it that the company has secured permission to import pharmaceutical formulations of new drug for ...

1don MSN

Guggenheim lifts AstraZeneca stock target, buy rating on prospects

Guggenheim adjusted its price target on shares of AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN), increasing it to GBP13,100 from ...

Pharmaceutical Technology2d

COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

FiercePharma1d

AstraZeneca's Calquence and Amgen's Lumakras clinch FDA label expansions

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

GlobalData on MSN3d

JP Morgan 2025: AstraZeneca promises a ‘catalyst-rich’ year ahead

CFO Aradhana Sarin outlined AstraZeneca’s plans at the 2025 JP Morgan Healthcare Conference in San Francisco on 15 January. The company maintains a confident outlook for the new year, said Sarin, ...

AstraZeneca Files Flurry of Lawsuits to Protect Cancer Treatment Drug

This complaint was first surfaced by Law.com Radar, ALM's source for immediate alerting on just-filed cases in state and federal courts. Law.com Radar now offers state court coverage nationwide. Sign ...

AstraZeneca gains on getting nod from CDSCO to import new drug Eculizumab

AstraZeneca Pharma India rose 1.10% to Rs 10,754 after the firm received approval from the Central Drugs Standard Control Organisation (CDSCO) to import pharmaceutical formulations of eculizumab ...

AstraZeneca rises Thursday, outperforms market

Shares of AstraZeneca PLC AZN rallied 1.84% to £108.44 Thursday, on what proved to be an all-around positive trading session ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results